ReviewBiomolecules2026
ELABELA: A Potential Therapeutic Target for Ischemia-Reperfusion Injury.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Different Doses of Ranolazine on SIRT1, APELA, and APL13 in a Rat MCAO Model.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemia-reperfusion injury (IRI) refers to a paradoxical pathological process in which ischemic tissues or organs sustain further damage upon the restoration of blood flow and is clinically commonly observed in the peripheral vascular systems and various vital organs. In 2013, the endogenous peptidic hormone ELABELA (ELA) was identified as a novel native ligand of the APJ G protein-coupled receptor, alongside apelin. ELA is constitutively expressed in a range of adult and embryonic tissues and plays a role in numerous physiological and pathological processes. In recent years, a rapidly growing body of research has highlighted the cytoprotective properties of ELA against IRI. In this review, we synthesize current research on the protective role of ELA in mitigating IRI across multiple organ systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.